This document discusses gastrointestinal reflux disease (GERD) and approaches to treating it. It begins by defining GERD and describing its typical clinical presentations. It notes that lifestyle factors like obesity have only weak evidence of aggravating GERD symptoms. Certain medications are also described as potentially aggravating GERD. The document then discusses the phenotypic classification of GERD and reviews the symptoms. It provides data on the prevalence of GERD worldwide and in particular countries and regions. Reasons for treatment failure with proton pump inhibitors are summarized. New therapies for GERD like vonoprazan, a potassium-competitive acid blocker, are introduced and its advantages over proton pump inhibitors are highlighted. Clinical evidence is presented demonstrating
Esomeprazole works by binding irreversibly to the H+/K+ ATPase in the proton pump.
Inhibition dramatically decrease the secretion of hydrochloric acid into the stomach
Esomeprazole Product Presentation for MPO's.
The primary uses of esomeprazole are gastroesophageal reflux disease, treatment and maintenance of erosive esophagitis, treatment of duodenal ulcers caused by H. pylori, prevention of gastric ulcers in those on chronic NSAID therapy, and treatment of gastrointestinal ulcers associated with Crohn's disease.
Review of new alerts on PROTON PUMP INHIBITORS (PPI) adverse effects 2016 UPD...PAWAN V. KULKARNI
Last Updated: 15th MAY: ALL NEW STUDIES INCLUDED. After more than 2 decades of USE, ABUSE, OVERUSE.... PPIs are under scanner. Not just Osteoporosis, other complications but Proton pump inhibitors have been confirmed to cause insistent Kidney failure/disease, heart attacks to name a few. This new revelations should open the eyes of so many consumers and several doctors.
Peptic Ulcer Disease Affects All Age Groups. Can occur in children, although rare. Duodenal ulcers tends to occur first at around the age 25 and continue until the age of 75. Gastric ulcers peak in people between the ages of 55 and 65. Men Have Twice The Risk as Women Do
VILDAGLIPTIN: DPP-IV INHIBITOR
Generic name: Vildagliptin
Brand name: Galvus
Treatment for: type 2 diabetes
selective inhibitor of dipeptidyl-
peptidase IV (DPP-IV)
- the first in a new class of oral antidiabetic agents
- known as dipeptidyl peptidase IV inhibitors
(DPP-IV) inhibitors
Esomeprazole works by binding irreversibly to the H+/K+ ATPase in the proton pump.
Inhibition dramatically decrease the secretion of hydrochloric acid into the stomach
Esomeprazole Product Presentation for MPO's.
The primary uses of esomeprazole are gastroesophageal reflux disease, treatment and maintenance of erosive esophagitis, treatment of duodenal ulcers caused by H. pylori, prevention of gastric ulcers in those on chronic NSAID therapy, and treatment of gastrointestinal ulcers associated with Crohn's disease.
Review of new alerts on PROTON PUMP INHIBITORS (PPI) adverse effects 2016 UPD...PAWAN V. KULKARNI
Last Updated: 15th MAY: ALL NEW STUDIES INCLUDED. After more than 2 decades of USE, ABUSE, OVERUSE.... PPIs are under scanner. Not just Osteoporosis, other complications but Proton pump inhibitors have been confirmed to cause insistent Kidney failure/disease, heart attacks to name a few. This new revelations should open the eyes of so many consumers and several doctors.
Peptic Ulcer Disease Affects All Age Groups. Can occur in children, although rare. Duodenal ulcers tends to occur first at around the age 25 and continue until the age of 75. Gastric ulcers peak in people between the ages of 55 and 65. Men Have Twice The Risk as Women Do
VILDAGLIPTIN: DPP-IV INHIBITOR
Generic name: Vildagliptin
Brand name: Galvus
Treatment for: type 2 diabetes
selective inhibitor of dipeptidyl-
peptidase IV (DPP-IV)
- the first in a new class of oral antidiabetic agents
- known as dipeptidyl peptidase IV inhibitors
(DPP-IV) inhibitors
Gastroesophageal Reflux Disease (GERD) is a common disorder that has undergone many paradigm changes in the last 15 years. We discuss the current paradigms in the pathophysiology, diagnosis and management of GERD.
GERD ( Gasrtro-esophageal reflux disease )
Gastroesophageal reflux disease (GERD) is a condition in which the stomach contents (food or liquid) leak backwards from the stomach into the esophagus (the tube from the mouth to the stomach). This action can irritate the esophagus, causing heartburn and other symptoms.
And Case study at the end
GERD is most common gastric problem in community affecting large number of people. Diagnosis and management is very simple with understanding.
http://www.youtube.com/c/DrDhavalMangukiyaGastrosurgeonSurat
https://gastrosurgerysurat.blogspot.com/
https://drdhavalmangukiya.com/
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
VONAPRAZAN presentation.pptx
1. NEW ERA IN PEPTIC ULCER Disease
-
SAJID KHAN PESHAWAR
PAKISTAN
An O ld Disease with New
Approaches
2. What is GERD?
GERD should be defined as symptoms or
complications resulting from the reflux of gastric
contents into the esophagus or beyond, into the
oral cavity (including larynx) or lung.
4. There is only weak evidence that lifestyle factors
aggravate GERD symptoms
• Obesity:
• severity of esophagitis correlates with weight only when
BMI >30 kg/m 2
• contradictory studies into weight loss indicate no
effect/improvement in GERD.
• Smoking:
• lowers LES pressure and the acid -neutralising effect of
saliva.
• Physical activity:
• running might provoke GERD by increasing TLESRs.
Meining A et al. Am J Gastroentero 2000;95:2692.
5. Medications mayaggravate
GERD symptoms
Impairment of LES function:
• beta-adrenergic agonists
• theophylline
• anticholinergics
• tricyclic antidepressants
• progesterone
• alpha-adrenergic antagonists
• diazepam
• calcium channel blockers.
Damage to the esophageal
mucosa:
• acetylsalicylic acid and other
NSAIDs
• tetracycline
• quinidine
• bisphosphates.
6. Phenotypic Classification of GERD
GERD
NERD*
Erosive
Esophagitis
Barrett’s
Esophagus
Fass et al. Alim Pharm Ther 2005
*NERD: Non - Erosive Reflux Disease
Barrett's esophagus is a condition in which tissue that is
similar to the lining of your intestine replaces the tissue lining
your esophagus. People with Barrett's esophagus may
develop a rare cancer called esophageal adenocarcinoma
7. What are the Symptoms of GERD?
• Heartburn
• Regurgitation
• Chest pain
• Impaired QOL
• Others (burning mouth/tongue)
• Atypical (“supraesophageal”) symptoms
• These are the same symptoms as patients with erosive esophagitis
and Barrett’s esophagus
• The severity of these symptoms CANNOT PREDICT the subtype of
GERD into which a patient falls prior to endoscopic examination
10. Indications for additional investigations
• Atypical history.
• Symptoms are frequent and long -standing or do not respond to
therapy.
• Alarm symptoms are present:
• severe dysphagia
• weight loss
• bleeding
• hematemesis
• mass in the upper abdomen
• anemia
11. What are the Symptoms of
Symptomatic GERD?
•
Heartburn
• Regurgitation
• Chest pain
• Impaired QOL
• Others (burning mouth/tongue)
• Atypical (“supra esophageal”) symptoms
• These are the same symptoms as patients with erosive esophagitis
and Barrett’s esophagus
• The severity of these symptoms CANNOT PREDICT the subtype of
GERD into which a patient falls prior to endoscopic examination
13. US
18.1 % to 27.8%
Ref. https://www.ncbi.nlm.nih.gov/books/NBK441938/
EU
8.8 % to 25.9%
Ref. World J Gastroenterology. 2017 Jan 21; 23(3): 525 – 532.
Prevalence of GERD Worldwide
14. Prevalence of GERD,Peptic Ulcer &
H . pylori infection in Pakistan
Ref. Journal of Pakistan Medical Association. Volume 42, Issue 9
Professional Medical Joiurnal. Vol 17 No 03 (2010): Vol. 17 No. 03
Disease Burden in
Pakistan
Pakistan spend nearly 27
Billion PKR annually for acid
related Diseases.
IMS data 2021
The age adjusted rate
of gastric ulcer patients
shows that 0.7 males and 0.3
females/ 10,000 population of
Karachi might be suffering
from gastric ulcer .
( )
Among PUD Patients
Prevalence of infection
with H. pylori varied to
92 % in Pakistani
population
In Pakistan 24 % of the
population is suffering
from GERD
Ref. Journal of the College of Physicians
and Sureons - - Pakistan: JCPSP 15(9):532 -4
15. • Helicobacter pylori ( H. pylori) infection is one
of the most common chronic bacterial infections
in humans affecting approximately 4.4 billion
people worldwide, with a prevalence of 28 % to
84 % in different populations
• Globally Peptic ulcer disease affects
approximately 4.6 million people annually.
Prevalence of H. pylori infection and Peptic
Ulcer Worldwide
Clinical — alimentary tract| volume 153, issue 2, p420 - 429 , august 1, 2017
Peptic ulcer. OMICS International. August 1, 2019
17. PPIs have been used for more than a quarter-century as a first-line
treatment for these diseases, it has become clear that there are some
issues in need of improvement.
It takes several days to show maximal effect.
Reflux symptoms of GERD are not sufficiently relieved after the first
dose of PPI in 2/3 patients due to slow onset of the action, 1/3 of
patients still have symptoms even after 3 days of treatment.
Effects of PPI are influenced by cytochrome p450 (CYP) 2C19
polymorphism.
Unsatisfactory effects at night • Requires an acidic environment for
activation, PPI are unstable in acidic conditions
18. To overcome the mentioned unmet needs, alternative formulations of
conventional PPIs and new H+K +ATPase inhibitors have been established.
Immediate-release Omeprazole and Dex lansoprazole modified release (MR),
which improve nocturnal acid breakthrough (NAB)
Dex lansoprazole MR is a R-enantiomer of lansoprazole and is a PPI with dual
delayed-release formulation Dual release system in the duodenum and small
intestine gives 2 peak concentrations within 2 hours and 5 hours after
administration.
% time 24-hour intragastric pH › 4 of Dex lansoprazole MR 60 mg and
lansoprazole 30 mg once daily for 5 days administration was 71% and 60%,
respectively
20. Survey of Satisfaction Status with PPI’s
Patients dissatisfied
with PPI
Physicians
dissatisfied with PPI
Ref: Digestive Diseases and Sciences volume 55, pages3415 - 3422 (2010)
1000 patients & physicians survey in the US
22. Current therapies including
PPIs, have limited response due
to:
1. Slow onset of action
2. Insufficient duration of acid control
Which results in..
Nocturnal
heartburn
Postprandial
heartburn
J.Neurogastroenterol Motil, Vol. 24 No. 3 July,
2018
Which can leads to..
23. Unmet need ,limitations of ppi’s
Molecule % Time pH>4 a No. Hours pH>4 b Mean pH
Esomeprazole 58.43 % 14 hours 4.04
Rabeprazole 50.53 % hours
12.1 3.70
Omeprazole 49.16 % hours
11.8 3.54
Lansoprazole 47.98 % hours
11.5 3.56
Pantoprazole %
41.94 10.1 hours 3.33
Ref: Current Diagnosis & Treatment 2020 (Gastro)
3rd
edition 2020
Chapter 11 ,Page 163 Table 11-5
a. Percentage of time that intragastric pH was 4.0
b. Mean 24-Hour intragastric pH on Day 5 by treatment group
PPI’s are unable to maintain pH>4
24. Reflux symptoms persist after 1 st
dose
Symptoms persist after 3 days
Heartburn & regurgitation not relieved
Patients used twice daily PPI
Addition of another antacid required with PPI
Unmet needs of Patients with PPI
treatments
66 %
50 %
40 %
22 %
42 %
J.Neurogastroenterol Motil, Vol. 24 No. 3 July, 2018
26. Mode of Action
Vonoprazan is a Potassium
Competitive Acid Blocker
(P -CAB) and Inhibits acid
secretion by Competitively
Blocking availability of
potassium to hydrogen -
potassium ATPase.
J.Neurogastroenterol Motil, Vol. 24 No. 3 July, 2018
27. Advantages of P -CAB
VS
Activated drug needs no
(
activation also stable in acid)
hours half
>7 -life
No dependency on meal
Limitations of PPIs
Prodrug need acid for activation
(
but active drug is unstable in acid)
<2 hours half -life
Meal required for activation
(one hour before meal recommended )
Comparison PPI V/S P -CAB
30. Acid - inhibitory effects of Vonoprazan 20 mg compared with
esomeprazole 20 mg
Ref. Sakurai et al, Alimentary Pharmacology and Theraputics,2015
Method:
Randomized, open -label study, vonoprazan 20 mg and esomeprazole 20 mg (Study
V vs. E) were orally administered daily for 7 days.
Result:
• Acid -inhibitory effect (pH4 HTR) of vonoprazan was significantly greater than
that of esomeprazole on both Days 1 and 7; Day 7 difference in pH4 HTR for
vonoprazan vs. esomeprazole was 24.6 % .
• The Day 1 to Day 7 ratio of 24 -h pH4 HTRs was >0.8 for vonoprazan ,
compared with 0.370 for esomeprazole.
pH above 4 maintenance Study
31. Rapid and Potent acid control
Ref. Sakurai et al, Alimentary Pharmacology and Theraputics,2015
pH above 4 maintenance Study
32. Vonoprazan versus lansoprazole for the initial relief of
heartburn in patients with Erosive esophagitis
Ref. Oshima et al.AP&T 2018. Aliment Pharmacol Ther.2019;49:140 -146
Methods:
Patients (n = 32) with erosive esophagitis who experienced heartburn at least
once a week were randomized in a double -blind manner to receive either daily
vonoprazan (20 mg) or lansoprazole (30 mg) before breakfast for 14 days.
Results:
• Heartburn was relieved sooner with vonoprazan than with lansoprazole ( P <
0.05 ).
• Heartburn was completely relieved in Vonoprazan (31.3 % ) than
lansoprazole (12.5%) of patients on day 1, respectively.
• Significantly more patients achieved complete nocturnal heartburn relief with
vonoprazan than lansoprazole ( P < 0.01 ).
Vonoprazan efficacy in Nocturnal
Heart burn
33. Vonoprazan demonstrated a faster time to complete heart burn
relief than Lansoprazole, and this complete relief was most
pronounced for night time heart burn.
Ref. Oshima et al.AP&T 2018. Aliment Pharmacol Ther.2019;49:140 -146
Better Heart burn relief with Vonoprazan Vs PPI
Vonoprazan efficacy in Nocturnal
Heart burn
34. Vonoprazan, a novel potassium competitive acid blocker,
vs. lansoprazole for the healing of Erosive oesophagitis
Ref. Ashida et al, Aliment Pharmacol ther 2016
Method:
In this multicenter, randomized, double -blind, parallel-group comparison study,
patients with endoscopically confirmed EE (LA Classification Grades A–D) were
randomly allocated to receive vonoprazan 20 mg or lansoprazole 30 mg once daily
after breakfast
Result
The proportion of patients with healed EE up to week 8 was 99.0% for vonoprazan
and 95.5% for lansoprazole, thus verifying the non-inferiority of vonoprazan (P <
0.0001).
Erosive Esophagitis Study
35. Superior healing rate in Erosive
Esophagitis
Ref. Ashida et al, Aliment Pharmacol ther 2016
36. Maintenance for healed erosive esophagitis: Phase - 3
comparison of vonoprazan with lansoprazole
Ref. Ashida et al,Aliment Pharmacol Ther 2018
Methods
•607 patients aged ≥ 20 years.
•All patients in whom endoscopic healing of EE was confirmed 2, 4, or 8 wk
after the start of the study medication were immediately stratified by
baseline endoscopic LA Classification grade (A/B or C/D).
•Subsequently randomized in a 1:1:1 ratio to receive maintenance therapy
with vonoprazan 10 mg (n = 202), vonoprazan 20 mg (n = 204), or
lansoprazole 15 mg (n = 201) given once daily after breakfast for 24 wk.
Maintenance Study
37. Minimal recurrence of Erosive
Esophagitis
Ref. Ashida et al,Aliment Pharmacol Ther 2018
Lansoprazole 15mg
38. Results
• Rates of EE recurrence during the 24 - wks.maintenance period were 16.8%
(lansoprazole 15 mg), )
5.1 % (vonoprazan 20 mg , and 2.0 %
( vonoprazan 10 mg) , respectively. Vonoprazan was shown to be non -
inferior to lansoprazole 15 mg ( P < 0.0001 for both doses).
• Recurrence rates in patients with baseline LA grade C/D EE were significantly
reduced with vonoprazan 10 mg (13.2%) and 20 mg (4.7%) vs
lansoprazole 15 mg (39.0%) ( P = 0.0114 and P = 0.0001 , respectively).
Conclusion
Vonoprazan was shown to be non -inferior to lansoprazole 15 mg at both
investigated doses.
Maintenance for healed erosive esophagitis: Phase - 3
comparison of vonoprazan with lansoprazole
Ref. Ashida et al,Aliment Pharmacol Ther 2018
Minimal recurrence of Erosive
Esophagitis
39. Vonoprazan, a novel potassium - competitive acid blocker,
as a component of 1 st
and 2 nd
line triple therapy for
Helicobacter pylori eradication
Ref. Murakami K, et al. Gut 2016;65:1439 – . doi:10.1136/gutjnl
1446 - 2015 - 311304
Method:
Randomized, double -blind, multicenter, parallel -group study
was conducted to verify the noninferiority of vonoprazan 20 mg
to lansoprazole 30 mg as part of first -line triple therapy (with
amoxicillin 750 mg and clarithromycin 200 or 400 mg) in H
pylori positive patients with gastric or duodenal ulcer history.
Eradication of H. pylori infection
40. Better eradication of H. pylori
infection
Ref. Murakami K, et al. Gut 2016;65:1439 – 1446 . doi:10.1136/gutjnl - 2015 - 311304
41. Vonoprazan, a novel potassium - competitive acid blocker,
as a component of 1 st
and 2 nd
line triple therapy for
Helicobacter pylori eradication
Ref. Murakami K, et al. Gut 2016;65:1439 – 1446 . doi:10.1136/gutjnl - 2015 - 311304
Conclusion
Vonoprazan is effective as part of first - line triple therapy and as
part of second - line triple therapy in H pylori - positive patients
with a history of gastric or duodenal ulcer.
Better eradication of H. pylori
infection
42. • Rapid Onset of action
• Potent Acid control
• Durable 24 - Hrs activity (Controls nocturnal heartburn
and breakthrough)
• Can be taken with or without food
• Better safety profile
Summary Features
43. Disease Dose Duration
Reflux esophagitis (EE) 20 mg Once a day 4 to 8 weeks
Maintenance of Healing
Esophagitis
10 mg Once a day
-
Gastric Ulcer 20 mg Once a Day 8 weeks
Duodenal Ulcer 20 mg Once a Day
6 weeks
Prevention of NSAID induce
Ulcer
10 mg Once a Day -
H. pylori Eradication
20 mg Twice daily with triple
drug regimen
01 week
Dosage